Aastrom Biosciences, Inc. (Nasdaq:ASTM) the leading developer of patient-specific, multicellular therapies for the treatment of severe, chronic cardiovascular diseases will presents Top-line 12-Month Results from the Phase 2b RESTORE-CLI Clinical Trial today- Wednesday, June 1, 2011 at 4:30 pm (EDT).
The conference call will be available live in the Investors section of Aastrom's website at http://www.aastrom.com/investor.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.
To participate in the live call by telephone, please call (877) 312-5881 and reference Aastrom's Top-Line 12-Month RESTORE-CLI results conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173. The conference ID is 69467531.
If you are unable to participate during the live call, the webcast will be available for replay at http://www.aastrom.com/events.cfm until Wednesday, August 31, 2011. A replay of the call will also be available until 11:59 pm (EDT) on Saturday, June 11, 2011, by calling (800) 642-1687, or from outside the U.S. at (706) 645-9291. The conference ID is 69467531.
We have covered the Aastrom story quite actively this past year and we believe the final data presentation from the RESTORE-CLI trial results should continue to push shares higher. Already it is nice to see shares back to the levels where they were before the most recent sell-offs.
Here are some of the catalysts we expect for ASTM:
Report final 12-month data from the Phase 2 RESTORE-CLI trial (today)
Initiate a Phase 3 trial in no-option CLI patients (2Q11)
Report 12-month data from Phase 2 IMPACT-DCM trial in surgical DCM patients and 6-month interim results from Phase 2 trial in catheter DCM patients (3Q11)
Initiate a Phase 3 trial in poor-option CLI patients (4Q11) - Initiate a RCT Phase 2 study in catheter DCM patients (early 2012)
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites